Stephens Inc Neurocrine Biosciences Inc Transaction History

Stephens Inc

$6.77 Billion
Q3 2024

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 06, 2024	BUY	$130.86 - $143.19 $15,834 - $17,325	121 Added 4.73%	2,679 $368,000
Q1 2024 May 15, 2024	SELL	$130.4 - $143.74 $564,632 - $622,394	-4,330 Reduced 62.86%	2,558 $352,000
Q4 2023 Feb 13, 2024	BUY	$106.07 - $132.76 $101,296 - $126,785	955 Added 16.1%	6,888 $907,000
Q2 2023 Aug 14, 2023	BUY	$89.53 - $104.87 $4,386 - $5,138	49 Added 0.83%	5,933 $559,000
Q1 2023 May 15, 2023	SELL	$94.11 - $123.02 $15,622 - $20,421	-166 Reduced 2.74%	5,884 $595,000
Q3 2022 Nov 02, 2022	SELL	$92.03 - $107.81 $7,730 - $9,056	-84 Reduced 1.37%	6,050 $643,000
Q2 2022 Aug 03, 2022	BUY	$75.79 - $100.07 $3,562 - $4,703	47 Added 0.77%	6,134 $598,000
Q1 2022 May 04, 2022	BUY	$72.45 - $94.81 $40,644 - $53,188	561 Added 10.15%	6,087 $571,000
Q4 2021 Mar 07, 2022	SELL	$79.65 - $106.22 $61,330 - $81,789	-770 Reduced 12.23%	5,526 $471,000
Q3 2021 Oct 27, 2021	BUY	$86.18 - $99.03 $45,158 - $51,891	524 Added 9.08%	6,296 $604,000
Q2 2021 Aug 12, 2021	BUY	$89.43 - $102.27 $10,373 - $11,863	116 Added 2.05%	5,772 $562,000
Q1 2021 May 14, 2021	BUY	$87.57 - $119.4 $495,295 - $675,326	5,656 New	5,656 $550,000
Q4 2020 Feb 10, 2021	SELL	$86.91 - $108.33 $485,218 - $604,806	-5,583 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$96.16 - $135.15 $26,059 - $36,625	271 Added 5.1%	5,583 $537,000
Q1 2020 May 14, 2020	BUY	$75.11 - $113.76 $398,984 - $604,293	5,312 New	5,312 $460,000
Q4 2019 Feb 14, 2020	SELL	$86.8 - $118.57 $463,512 - $633,163	-5,340 Closed	0 $0
Q3 2019 Oct 18, 2019	BUY	$83.82 - $101.5 $70,408 - $85,260	840 Added 18.67%	5,340 $481,000
Q3 2018 Nov 14, 2018	BUY	$98.88 - $125.85 $444,960 - $566,325	4,500 New	4,500 $553,000
Q3 2017 Nov 08, 2017	SELL	$47.97 - $61.28 $215,865 - $275,760	-4,500 Closed	0 $0
Q2 2017 Aug 10, 2017	BUY	N/A	4,500	4,500 $207,000

Others Institutions Holding NBIX

# of Institutions

627

Shares Held

94.3M

Call Options Held

632K

Put Options Held

621K

Black Rock Inc. New York, NY

14.2M
Shares

$1.8 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

10M
Shares

$1.27 Billion
0.02% of portfolio
State Street Corp Boston, MA

5.15M
Shares

$654 Million
0.02% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

2.57M
Shares

$327 Million
0.47% of portfolio
Bellevue Group Ag Kuesnacht, V8

1.86M
Shares

$237 Million
3.62% of portfolio

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12.2B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Stephens Inc , based on Form 13F filings with the SEC.

News

Stay updated on Stephens Inc with notifications on news.

Account